Lysyl oxidase drives ccRCC progression by coordinating HIF-2α transcription program with tumor microenvironment

Technical Summary: Lysyl Oxidase Drives ccRCC Progression by Coordinating HIF-2α Transcription Program with Tumor Microenvironment

Problem Statement
Clear cell renal cell carcinoma (ccRCC) is primarily driven by the loss of the VHL tumor suppressor, leading to the constitutive stabilization of hypoxia-inducible factor 2-alpha (HIF-2α) even under normoxic conditions. While HIF-2α drives angiogenesis and tumor progression, the mechanisms sustaining its proteostasis and transcriptional activity in the heterogeneous tumor microenvironment (TME) remain poorly defined. Furthermore, current therapies targeting HIF-2α (e.g., belzutifan) or angiogenesis (e.g., VEGFR inhibitors) face limitations including on-target toxicities, rapid adaptive resistance, and the emergence of resistance-conferring mutations (e.g., HIF-2α G323E) that impair drug binding. There is an urgent need to identify novel molecular drivers that coordinate intracellular HIF-2α signaling with extracellular matrix (ECM) remodeling to overcome these therapeutic barriers.

Methodology
The study employed a multi-modal approach combining computational biology, molecular biology, and in vivo modeling:

• Single-Cell Transcriptomics: The authors analyzed 59 intra-tumoral gene expression programs from 19 RCC specimens using single-cell RNA sequencing (scRNA-seq). They utilized Gene Expression Program 60 (GP60), a hypoxia-EMT-associated malignant program, to identify top-ranked genes.
• Correlation and Survival Analysis: Bulk RNA-seq data from TCGA-KIRC and GEO datasets were used to correlate LOX expression with clinical outcomes (disease-free survival) and HIF-2α activity.
• Molecular Mechanism Dissection:
  • Proteostasis: Cycloheximide chase assays, proteasome/lysosome inhibition, and ubiquitination assays were used to determine HIF-2α stability.
  • Enzymatic Activity: In vitro oxidation assays using recombinant LOX and bead-bound HIF-2α, followed by biotin-hydrazide labeling, confirmed direct lysine oxidation.
  • Interaction Studies: Proximity ligation assays (PLA), co-immunoprecipitation, and ChIP-qPCR assessed physical interactions between LOX, HIF-2α, and the E3 ligase HUWE1.
  • Genetic/Pharmacological Perturbation: CRISPR-mediated knockout (sgLOX), inducible knockdown (shLOX), and treatment with the small-molecule LOX inhibitor LXG6403 were used to validate function.
• In Vivo Models: Xenograft models (786-O, A498, A704) and patient-derived xenografts (KP178 PDX) were utilized to assess tumor growth, metastasis, and angiogenesis. Models included HIF-2α-deficient cells reconstituted with wild-type or G323E mutant HIF-2α to test resistance.
• Clinical Validation: Immunohistochemistry (IHC) and quantitative image analysis were performed on a tissue microarray (TMA) of 206 ccRCC patient tumors to correlate nuclear LOX and HIF-2α levels with tumor grade.

Key Contributions and Results

1. Identification of LOX as a Driver: Single-cell analysis identified LOX as a top-ranked gene within the aggressive GP60 hypoxia-EMT program. High LOX expression in ccRCC tumors correlated significantly with worse disease-free survival and was enriched in malignant cells compared to normal kidney tissue.
2. Mechanism of HIF-2α Stabilization: The study reveals a novel, non-canonical mechanism where LOX directly oxidizes lysine residues on HIF-2α. This oxidation antagonizes the binding of the E3 ubiquitin ligase HUWE1, thereby preventing HIF-2α ubiquitination and proteasomal degradation. Consequently, LOX sustains HIF-2α protein levels and its chromatin occupancy on target promoters (e.g., VEGFA, SERPINE1).
3. Dual Role in Tumor and Microenvironment: LOX inhibition (genetic or pharmacological via LXG6403) simultaneously:
   • Intracellular: Destabilizes HIF-2α, reduces clonogenicity, impairs epithelial-mesenchymal transition (EMT), and suppresses tumor-initiating capacity (sphere formation).
   • Extracellular: Disrupts ECM organization (collagen crosslinking) and inhibits angiogenesis by reducing VEGF and other pro-angiogenic factors.
4. Therapeutic Efficacy and Resistance Overcoming:
   • LOX inhibition significantly suppressed tumor growth in xenografts and PDX models.
   • It enhanced the efficacy of anti-angiogenic therapy (lenvatinib) when used in combination.
   • Crucially, LOX inhibition remained effective in tumors harboring the belzutifan-resistant HIF-2α G323E mutation, whereas belzutifan failed to inhibit growth in these models. This is attributed to LOX targeting HIF-2α stability rather than its dimerization pocket.
5. Clinical Correlation: In high-grade (Grade III/IV) ccRCC patient tumors, there was a strong positive correlation between nuclear LOX and nuclear HIF-2α levels, a relationship not observed in low-grade tumors. This suggests nuclear accumulation of LOX is a feature of advanced, aggressive disease.

Significance
The paper establishes LOX as a central regulator that coordinates intracellular HIF-2α signaling with extracellular tumor microenvironment remodeling in ccRCC. By identifying LOX-mediated lysine oxidation as a critical mechanism for sustaining HIF-2α stability, the study offers a new explanation for the persistence of HIF-2α activity in advanced VHL-deficient tumors. Therapeutically, targeting LOX presents a multi-pronged strategy that destabilizes HIF-2α independently of PAS-B domain integrity, thereby bypassing resistance mechanisms associated with current HIF-2α inhibitors. Furthermore, by simultaneously disrupting angiogenesis and ECM architecture, LOX inhibition addresses both tumor-intrinsic and tumor-extrinsic drivers of progression, offering a potential solution to the limitations of current standard-of-care therapies in ccRCC.